Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × NSC 366140 × Clear all
NCT00003041 2013-01-31

Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Breast

Breast Neoplasms

NCT00002585 2012-03-12

Pyrazoloacridine in Treating Women With Metastatic Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡